Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy

Core Insights - Monopar Therapeutics Inc. has been identified as a promising investment opportunity, with Raymond James raising its price target from $80 to $142 while maintaining a Strong Buy rating [1][3] Financial Performance - In Q2 2025, Monopar reported a net loss of $2.5 million ($0.35 per share), an increase from a net loss of $1.7 million ($0.49 per share) in Q2 2024 [2] - The company has cash, cash equivalents, and investments totaling $53.3 million, which is expected to support operations through December 31, 2026 [2] Development Pipeline - The increased price target reflects confidence in the company's ability to execute its anticipated timeline, including filing an NDA for ALXN1840, completing its Phase 1 imaging/dosimetry trial for MNPR-101-Zr, continuing its Phase 1a therapeutic trial for MNPR-101-Lu, and advancing the preclinical MNPR-101-Ac program into the clinic [3]